BioCryst Pharmaceuticals has unveiled groundbreaking clinical data for ORLADEYO at the 2025 Meeting of the European Academy of Allergy and Clinical Immunology. The new findings demonstrate significant advancements in the HAE (Hereditary Angioedema) treatment landscape, particularly concerning pediatric patients. The data reveal ORLADEYO’s efficacy in reducing attack frequency and improving the quality of life for young patients living with HAE. This breakthrough positions ORLADEYO as a potentially game-changing oral therapy, offering new hope for children previously reliant on less convenient treatment methods. The results not only highlight the drug’s beneficial impact on managing HAE but also reinforce BioCryst’s commitment to innovation in rare disease therapeutics. By offering a more manageable treatment option, ORLADEYO could transform how pediatric patients and their families approach living with HAE, making day-to-day life significantly easier and more predictable.
Stock TitanNew data shows CLYM116 reduces key IgA nephropathy biomarkers by ~70%, supporting a 12-week dosing regimen
October 24, 2026
New data released by CLIMB Bio and MabWorks reveals that their investigational drug CLYM116 significantly reduces critical biomarkers associated with IgA nephropathy by approximately 70%.